Yup, I think you're right: anyone looking at KBIO right now is getting nervous: $20/share, down 50% today. But hey, at least KBIO has pricing power; DMRC doesn't. DMRC's customers are the federal government, which isn't in the habit of letting vendors charge premium prices and supermarket chains, whose profit margins are generally 1-2%. So I don't think Martin Shkreli has Bruce Davis on speed dial...
Yup, it's business as usual for DMRC:
Management already guiding for $4m in negative FCF for next year;
Issuing shares in private sales instead of buying back stock;
Their earliest core patents began expiring in 2012...but it doesn't matter because they licensed about 3/4 of their patents to IV for money that's long gone.
Management still singing the same tune since they went public: the future is just one big contract away. And a fresh batch of suckers drawn in every year to pay for the dream (and Bruce Davis's $1.7m pay package)...
Uh, Digimarc is hemorrhaging cash, analysts are lowering their loss-per-share estimates (again) and the stock trades at 9 times revenue.
Digimarc is doing just fine knocking itself down. I think you're assigning way too much influence to the short sellers. It's going up on basically no volume, meaning nobody, even bulls, are jumping on board. When this goes up on the back of major volume, then maybe I'll be interested.